Eurogin is part of the Informa Markets Division of Informa PLC

Informa
Informa

EUROGIN 2023 abstract submission is now open! Submission deadline: October 3, 2022

EUROGIN Program Highlights

A full overview of current scientific developments in the field of cervical cancer and other HPV related diseases

High-level Scientific Program


EUROGIN focuses on translating scientific and evidence-based research into clinical practice by offering a high quality and innovative scientific program drawn up by outstanding international leaders from the academic sector as well as professional and patient organizations. 

The program aims to foster future advancements by providing fundamental insights to physicians and young researchers.

60+ Scientific Sessions

A series of scientific sessions presenting the latest research

180 Faculty Members

World class speakers presenting the most pressing issues in the field of HPV and related-cancers 

5 Satellite Symposia

Organized by industry partners presenting the most recent findings, innovations and future developments

Accelerating detection and elimination of HPV and related cancers

Scientific Program Objectives

The EUROGIN program aims to promote excellence in the field and develop research, training, screening, prevention and information concerning HPV-related infections, pre-cancers, and cancers. Some program objectives include:

Review

Reviewing the burden and epidemiology of HPV associated diseases in lower genital tract, anus and head & neck.

Understand

Understanding the role of molecular testing in primary screening and prevention and their application in routine practice.

Integrate

Integrating the use of HPV prophylactic vaccines into clinical practice and understanding the impact and cost-effectiveness on public health.

Implement

Implementation of guidelines for cervical disease; screening and management of cervical abnormalities.

Explore

Exploring the uses of HPV DNA and mRNA testing in clinical practice in a rational and cost-effective way.

Adapt

Reviewing different tools and techniques available in the field of HPV infection diagnosis and adapt the most appropriate strategies for patients.

Anticipate

Anticipating trends in biomarkers and genotyping for diagnosis and prevention.

Compare

Comparing worldwide experience in the field of screening and prevention of cervical disease, including developed and developing countries.

2023 Program Committee

Scientific Committee Chairman

Joseph Monsonego


Gynecologist/Obstetrician
France

Congress
President

Jesper Bonde


Pathologist
Denmark

Congress
President

Jennifer Smith


Public Health Specialist
USA